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Disorders of the thyroid gland are among the most common conditions diagnosed and managed by pediatric
endocrinologists. Thyroid hormone synthesis depends on normal iodide transport and knowledge of its regulation
is fundamental to understand the etiology and management of congenital and acquired thyroid conditions such as
hypothyroidism and hyperthyroidism. The ability of the thyroid to concentrate iodine is also widely used as a tool
for the diagnosis of thyroid diseases and in the management and follow up of the most common type of
endocrine cancers: papillary and follicular thyroid cancer. More recently, the regulation of iodide transport has also
been the center of attention to improve the management of poorly differentiated thyroid cancer. Iodine deficiency
disorders (goiter, impaired mental development) due to insufficient nutritional intake remain a universal public
health problem. Thyroid function can also be influenced by medications that contain iodide or interfere with iodide
metabolism such as iodinated contrast agents, povidone, lithium and amiodarone. In addition, some environmental
pollutants such as perchlorate, thiocyanate and nitrates may affect iodide transport. Furthermore, nuclear accidents
increase the risk of developing thyroid cancer and the therapy used to prevent exposure to these isotopes relies on
the ability of the thyroid to concentrate iodine. The array of disorders involving iodide transport affect individuals
during the whole life span and, if undiagnosed or improperly managed, they can have a profound impact on
growth, metabolism, cognitive development and quality of life.
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Iodine, as its water-soluble iodide ion (I−), is the rate-
limiting substrate for thyroid hormone synthesis. The
availability of iodide depends on oral intake and the rec-
ommended daily allowances are summarized in Table 1.
Iodide is absorbed in the stomach and duodenum and
cleared by the kidney and the thyroid. Seventy to eighty
percent of the iodine body content is located in the thy-
roid gland and thyroid hormone synthesis requires a
series of regulated steps. Altered regulation or defects in
any of these steps can affect thyroid hormone synthesis
and secretion. Furthermore, the understanding of iodide
transport is used in the diagnosis, prevention and treat-
ment of thyroid disorders and knowledge about the
mechanisms underlying iodide transport is now applied to* Correspondence: liuska-pesce@uiowa.edu
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article, unless otherwise stated.treat advanced forms of thyroid cancer and non-thyroidal
malignancies.Iodine intake and absorption
Iodine, as iodide (I−), is available but not equally distrib-
uted in the environment. Most iodide is found in the
oceans (sea water has 50 μg/L) and deficient soils are com-
mon in mountainous areas, regions that were glaciated
and areas of frequent flooding; however, deficiency is also
a problem in some coastal and island populations [2-5].
Plants grown in iodine deficient soils have as low as
10 μg/kg of dry weight, while plants grown in iodine rich
soils have a concentration of 1 mg/kg. Overall, the nat-
ural iodine content of many foods and beverages is low
(3–80 μg per serving), while foods from marine origin
have a higher content. However, sea salt has negligible
amounts, as iodide in seawater is sublimated into thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Recommendations for iodine intake by age and
population group from the World Health Organization
(WHO), UNICEF and ICCIDD [1]
Age or population group Recommended daily
allowance (μg)
Pre-school children (0–59 months) 90
School children (6–12 years) 120
Adolescents and adults (above 12 years) 150
Pregnant and lactating women 250
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portant dietary sources of iodine in industrialized coun-
tries are breads containing iodized salt and milk [2].
Iodide absorption in the gastrointestinal tract is medi-
ated by the sodium-iodide symporter (NIS), which also
mediates the uptake of iodide into the thyroid follicular
cell (see Figure 1) [7,8]. Iodide is rapidly cleared from
the circulation by the thyroid gland and kidneys. Thy-
roid clearance varies depending on iodine intake, from
10% of absorbed iodide in healthy individuals to more
than 80% in chronic iodine deficiency [2].Figure 1 Mechanisms of Iodide transport in thyroid follicular cells. Th
symporter NIS, using the sodium gradient generated by the Na, K-ATPase.
is also important, likely for maintaining the membrane potential of thyroid
transporter mediate iodide efflux. TPO, using H2O2 generated by the DUOX
reaction that result in the synthesis of the iodothyronines T4 and T3. Iodina
and digested in lysosomes. T4 and T3 are excreted via MCT8 and other tra
DEHAL1 and the released iodide is recycled. Purple boxes represent steps i
oxidation, organification and coupling are mediated by TPO, represented in
recycling of iodide after digestion of iodinated thyroglobulin is represented
membrane is shown in the blue boxes.Iodide transport in thyroid cells
As illustrated in Figure 1, the NIS (SLC5A5), a member
of the solute carrier family 5, located at the basolateral
plasma membrane of the thyroid follicular cells actively
transports iodide into the thyroid using the electrochem-
ical gradient generated by the Na,K-ATPase [9-11]. This
process also requires a constitutive active potassium
channel consisting of the KCNQ1 and KCNE2 subunits
promoting potassium efflux [12-14]. Iodide efflux into
the follicular lumen is mediated in part by pendrin, in
conjunction with an as of yet unidentified channel. Pen-
drin (SLC26A4), a member of the multianion transporter
solute carrier 26 family, is a coupled electroneutral iod-
ide/chloride, iodide/bicarbonate, and chloride/bicarbon-
ate exchanger [15-17]. At the intraluminal side, iodide is
oxidized, a reaction that requires hydrogen peroxide
(H2O2). The oxidation of iodide is mediated by thyroid
peroxidase (TPO). TPO is also responsible for the io-
dination of selected tyrosil residues of thyroglobulin
(organification), forming monoiodotyrosine (MIT) and
diiodotyrosine (DIT) residues, and for the coupling of
MIT and DIT resulting in the formation of T3 and T4e first step in iodide uptake is mediated by the sodium-iodide
Active transport of potassium by the KCNE2/KCNQ1 potassium channel
cells. At the apical membrane, pendrin and another yet unidentified
2/DUOXA system mediates the oxidation, organification and coupling
ted thyroglobulin is taken into the cell by micro- and macropinocytosis
nsporters. The iodotyrosines MIT and DIT are dehalogenated by
n basal iodide uptake. Orange boxes represent apical iodide uptake,
green boxes. The generation of H2O2 is represented in aqua. The
in the red box. The secretion of thyroid hormones at the basolateral
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T3 is thyroglobulin (Tg), a large glycoprotein secreted
by the thyroid follicular cells [19,20]. H2O2 is generated
by the dual oxidase 2 (DUOX2), a calcium dependent
flavoprotein NADPH oxidase, which requires a maturation
factor known as DUOXA2 [21]. T3 and T4 are released into
the bloodstream, following micro- or macropinocytosis and
lysosomal digestion of thyroglobulin by endopeptidases and
exopeptidases [22-24]. Animal and cellular models suggest
that the monocarboxylate channel (MCT8/SLC16A2) is
involved in the efflux of thyroid hormones at the baso-
lateral membrane [25,26]. MIT and DIT are deiodinated
by the iodotyrosine dehalogenase, DEHAL1. This allows
the re-utilization of iodide within the thyroid cell [27].
The molar ratio of secreted T4 to T3 is 11 to 1 due to
intrathyroidal deiodination of T4 to T3 by type 1 and 2
deiodinases (D1 and D2) [28]. However, most T3 pro-
duction occurs in extrathyroidal tissues and both, T3
and T4 can be converted to inactive forms via deiodina-
tion of the inner ring, by either type 3 deiodinases (D3)
or D1 [29,30].
Regulation of iodide transport
Iodide transport is dependent on the nutritional avail-
ability of iodide and on the stimulation of the thyroid
stimulating hormone receptor (TSHR). Although the
TSHR is constitutively active, it is susceptible to en-
hanced activation by TSH [31,32]. In addition, iodide
uptake and organification are inhibited by high intracel-
lular concentrations of iodide. Other factors have been
shown to regulate iodide uptake, including thyroglobu-
lin, cytokines, growth factors and estradiol.
1) TSH
TSH stimulates thyroid hormone synthesis and
secretion. TSH is a glycoprotein with two subunits.
The α subunit is identical to the glycoprotein
hormones LH, FSH and hCG, whereas the β subunit
is specific for the four hormones. TSH is synthesized
and secreted in response to TSH releasing hormone
(TRH) from the hypothalamus. Thyroid hormones
negatively regulate the synthesis and secretion of
both TRH and TSH. TSH stimulation of the
G-protein coupled TSHR increases cAMP, which in
turn, stimulates NIS transcription, half-life and
subcellular distribution. TSH also upregulates the
expression of TPO, Tg and the endocytosis of
iodinated Tg [11] and increases the translocation of
pendrin to the apical membrane of the thyroid
follicular cell, thereby enhancing iodide efflux [33].
2) Iodide
Iodide is a major regulator of iodide accumulation
and organification. Iodine intake has a negative
effect on the expression of NIS and high doses ofiodide block thyroid hormone synthesis via
inhibition of organification (Wolff-Chaikoff effect)
[34-37]. The adaptation to the initial inhibitory
effect (the escape from the Wolff-Chaikoff effect)
occurs as a result of decreased iodide transport. The
escape is secondary to complex regulatory phenomena
that involve, among others, decreased NIS gene
transcription, increased NIS protein degradation
and decreased NIS activity [38-40].
3) Thyroglobulin (Tg)
A role for Tg as an intrinsic regulator of iodide
transport and thyroid hormone synthesis has been
proposed to explain the heterogeneity of thyroid
follicles and its differential expression of thyroid
genes. Tg has been shown to decrease the gene
expression of NIS, TPO, and DUOX [41-44].
4) Cytokines and growth factors
Cytokines such as TNF and interleukins inhibit
iodide uptake and NIS expression. Insulin like
growth factor 1 (IGF-1) affects thyroid hormone
synthesis by downregulating the expression of NIS
[10,45-47]. Transforming Growth Factor-β (TGF-β)
has been shown to downregulate iodide transport by
several mechanisms in different species, including
inhibition of mRNA expression of TSHR, TPO, NIS,
the Na, K-ATPase and thyroglobulin [48].
5) Estradiol
Estradiol downregulates the expression of NIS and
iodide uptake in thyroid cells, possibly explaining the
higher incidence of goiter in women. Estradiol also
upregulates thyroglobulin [49,50].
Thyroid conditions as they relate to iodide transport
The different mechanisms and disorders associated with
abnormal iodide transport are summarized in Table 2.
For detailed explanation, please refer to the text.
Disorders of iodine intake (DII)
Iodine deficiency causes hypothyroidism and goiter.
Moreover, it is associated with an increased risk for
abortion and stillbirths, congenital malformations, in-
creased perinatal mortality, impaired growth and devel-
opmental retardation, impaired mental potential and
decreased productivity. Iodine deficiency in critical periods
of brain development and growth causes severe and per-
manent growth and cognitive impairment (cretinism) as
thyroid hormones are required for myelination, neuronal
differentiation and formation of neural processes in the
cerebral cortex, the basal ganglia and the inner ear during
the first trimester of gestation, and subsequently for brain
growth and differentiation [11,51-58]. Importantly, preg-
nant women need higher amounts of iodide (Table 1).
Even mild iodine deficiency during pregnancy may affect
outcomes [54,59-61]. However, despite the efforts from
Table 2 Mechanisms and disorders associated with abnormal iodide transport
Etiology Conditions, drugs or environmental agents
affecting this step in iodide transport
Manifestations









• Cretinism with neurological deficits and mental retardation
Child and adolescent:
• Growth retardation and delayed puberty
Child, adolescent and adult:
• Impaired mental function
• Hypothyroidism
• Increased risk to develop iodide induced-hyperthyroidism
and toxic nodular goiter after exposure to iodine
Abnormal basal iodide uptake NIS mutations (autosomal recessive) Congenital hypothyroidism, typically with goiter. Iodide-
trapping defect with little or no uptake of radioactive iodide
both at the thyroid and salivary gland level
Perchlorate, thiocyanate and nitrates Increased risk of goiter development and hypothyroidism,
specially in iodine deficient populations
Goitrogens (soy and other flavonoids,
glucosinolates and cyanogenic glucosides)
Increased risk of goiter development and hypothyroidism in
iodine deficient populations
Apical iodide efflux Pendred syndrome. Mutations in the SLC26A4
gene (autosomal recessive)
Sensorineural hearing loss, variable phenotype of goiter and
hypothyroidism and partial organification defect
Congenital hypothyroidism with atrophic
thyroid gland associated with SLC26A4
mutations (autosomal recessive)
Congenital hypothyroidism
Organification and coupling Tg gene mutations (autosomal recessive) Congenital hypothyroidism and/or variable degrees of goiter
and hypothyroidism with low Tg levels
TPO gene mutations (autosomal recessive) Congenital hypothyroidism and/or variable degrees of goiter
and hypothyroidism with partial or total organification defects
Mutations in DUOX2 or DUOXA2 (autosomal
recessive or dominant)
Transient or permanent congenital hypothyroidism
Anti-thyroid medications (i.e. PTU, methimazole,
carbimazole)
Medication-induced hypothyroidism
Recycling of iodide Mutations in DEHAL1 (autosomal recessive) Congenital hypothyroidism, goiter, increased MIT and DIT
serum levels and severe urinary loss of MIT and DIT
Thyroid hormone degradation
exceeds thyroid synthetic capacity
Overexpression of D3 in hemangiomas and
gastrointestinal stromal tumors
Consumptive hypothyroidism with elevated rT3 and resistance
to treatment with physiological doses of levothyroxine
Increased stimulation or
constitutive activity of the TSHR or
downstream pathways
TSHR stimulating immunoglobulins Graves’ disease
Transient congenital hyperthyroidism
TSHR activating mutations Sporadic congenital or autosomal dominant familial non-
autoimmune hyperthyroidism (germline mutations)
Toxic adenomas (somatic mutations)
Pregnancy hCG-induced gestational hyperthyroidism
Somatic, activating mutations of Gsα Toxic nodular hyperthyroidism and hyperthyroidism in
McCune Albright syndrome
Decreased stimulation or
inactivation of the TSHR or
downstream pathways
Presence of TSHR blocking immunoglobulins Hypothyroidism
Inactivating mutations of the TSHR (autosomal
recessive)
Resistance to TSH with overt or compensated hypothyroidism
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Table 2 Mechanisms and disorders associated with abnormal iodide transport (Continued)
Inactivating Gsα mutations Hypothyroidism in the context of pseudohypoparathyroidism
type Ia
Iodide mediated alterations in
thyroid function
Iodine containing solutions Transient hypothyroidism (Wolff-Chaikoff effect)
In iodine deficiency: Hyperthyroidism (Jod-Basedow)
Iodine containing contrast agents (iodine
containing IV contrasts)
Transient hypothyroidism (Wolff-Chaikoff effect)
In iodine deficiency: Hyperthyroidism (Jod-Basedow)
Amiodarone Amiodarone induced thyrotoxicosis (AIT): type 1: iodine
inducedthyrotoxicosis, Jod-Basedow type 2: thyroiditis
Amiodarone induced hypothyroidism (AMH); often associated
with underlying autoimmune thyroid disease
Other defects in thyroid hormone
release
Lithium Hypothyroidism due to decrease release of T4
Table 3 Epidemiological criteria for assessing iodine
nutrition based on median iodine urine concentration in











Pesce and Kopp International Journal of Pediatric Endocrinology 2014, 2014:8 Page 5 of 12
http://www.ijpeonline.com/content/2014/1/8the International Council for the Control of Iodine Defi-
ciency Disorders (ICCIDD) to end a preventable form of
hypothyroidism, goiter and mental retardation, thirty-two
countries and about 246 million schoolchildren are esti-
mated to have insufficient iodine intake [4,5]. In the US,
the median urinary iodine concentration decreased by
over 50% between the early 1970s and the early 1990s and
even though most of the US population remains iodine
sufficient, the aggregate data from NHANES 2007–2010
indicates that a subset of young women and pregnant
women may have mild iodine deficiency [3]. Popular foods
among young women, marketed for weight loss, are defi-
cient in iodine [62]. Furthermore, prenatal vitamins have
inconsistent amounts of iodide content [63,64]. Iodine
supplementation is recommended not only for pregnancy,
but also during lactation [65] as iodine supplementation
given to a lactating mother provides adequate iodine to
their infants [66]. Criteria for assessing iodine nutrition in
populations based on school age children and in pregnant
and lactating women are summarized in Table 3 [2,4,58].
Thyroglobulin is also a sensitive method to assess iodine
intake [67,68]. Disorders of iodide transport (see below)
are influenced by iodine intake. In addition, other ques-
tions remain, such as whether mild, transient congenital
and/or subclinical hypothyroidism could be impacted by
improving iodine intake.
Disorders of iodide transport









>500 ExcessiveMutations in the NIS gene
Homozygous or compound heterozygous
inactivating mutations of the NIS can cause
congenital hypothyroidism. The thyroid may be
normal at birth, but enlarges overtime due to
TSH stimulation, unless thyroid hormone
replacement is started. Affected individuals havean iodide-trapping defect with little or no uptake
of radioactive iodide both in the thyroid and the
salivary glands [69].2) Disorders associated with abnormal apical
iodide efflux
2.1) Pendred syndrome
Pendred syndrome is an autosomal recessive
disorder caused by mutations in the PDS/
SLC26A4 gene. It is characterized by
sensorineural hearing loss associated with
malformations of the inner ear (enlarged
vestibular system), variable degrees of goiter and
hypothyroidism and a partial iodine
organification defect diagnosed by the
perchlorate discharge test (see below) [17,70,71].2.2) Congenital hypothyroidism with hypoplastic
thyroid gland due to PDS/SLC26A4 mutations
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SLC26A4 gene in two individuals from two
families with hypoplastic thyroid glands. They
speculated that the hypoplasia may be caused by
“secondary atrophy”. However, the described
mutations have also been reported in patients
with Pendred syndrome, while the patients
described in this study had thyroid hypoplasia.
One case had apparently a normal hearing test.
Nevertheless, imaging studies of the inner ear
were not obtained. A second patient had deafness
and mental retardation. The authors did not
comment of the hearing function of the other
four patients with hypoplastic thyroid glands
harboring mutations on the SLAC26A4 gene.
Moreover, the thyroid volumes of the index
patients early in life are unknown [72]. Hence, it
is not clear if patients presenting with hypoplastic
thyroid glands may be within the spectrum of
Pendred syndrome or not, and the mechanism
causing thyroid atrophy needs to be further
elucidated; it could, e.g., involve destruction
of thyroid cells by the retained misfolded
proteins [17].3) Disorders of organification and coupling
3.1) Thyroglobulin (Tg)
Biallelic mutations in the Tg gene can cause
congenital hypothyroidism. The clinical
spectrum ranges from normal thyroid function
to overt hypothyroidism. The majority of
patients have congenital goiter or develop goiter
shortly after birth. The serum Tg concentrations
are very low. Affected individuals are
homozygous or compound heterozygous for
inactivating mutations. Defective Tg molecules
are typically retained in the ER and routed for
degradation. However, some truncated proteins
can be secreted and are sufficient for partial
thyroid hormone synthesis [19,73,74].3.2) Thyroid peroxidase (TPO)
Recessive TPO defects are among the most
common causes of congenital hypothyroidism
secondary to dyshormonogenesis. Patients may
have a partial or total organification defect. A
recent study in the Netherlands found that TPO
gene defects are the most common cause of a
total organification defect, as diagnosed by a
positive perchlorate test with a discharge
of > 90% [75].3.3) Dual oxidases and its chaperones (DUOX2/
DUOXA2)DUOX1 and DUOX 2 are NADPH flavoproteins
that share 83% sequence similarity. Both DUOX
genes are expressed in the thyroid but their
expression is not restricted to the thyroid. The
DUOX2 and DUOXA2 genes are contiguous
(together with their homologues DUOX1 and
DUOXA1) on the long arm of chromosome 15.
Only mutations in DUOX2 and in DUOXA2
have been found to cause congenital
hypothyroidism [21,76-78]. In some cases,
transient hypothyroidism occurs. This was
initially postulated to be secondary to
heterozygous mutations, while biallelic DUOX2
mutations were thought to cause permanent
hypothyroidism. However, transient
hypothyroidism also occurs in individuals with
biallelic mutations [77]. The role of DUOX1 in
compensating for the loss of DUOX2 is unclear
at this time and it is thought that iodide
availability may also affect the phenotype.4) Disorder of intra-thyroidal iodide recycling
4.1) Dehalogenase (DEHAL)
Mutations in the DEHAL1 gene (IYD) can cause
congenital hypothyroidism, goiter, increased
MIT and DIT serum levels and urinary loss of
MIT and DIT [27,79,80]. Variable mental deficits
can occur, depending on age of diagnosis and on
whether hypothyroidism occurs during
development [11,79].Disorders of abnormal iodide transport regulation
1) Conditions affecting TSH signaling
1.1) Hyperthyroidism
Conditions causing overstimulation of the TSHR
increase iodide uptake and thyroid hormone
synthesis. In Graves’ disease, the production of
TSHR-stimulating immunoglobulins causes
increased thyroid cell proliferation, iodide
uptake and thyroid hormone synthesis. These
IgG antibodies can cross the placenta and are
the most common cause of congenital
hyperthyroidism [31,32,81]. Rarely, activating
mutations of the TSHR are the cause of
excessive iodide uptake and hyperthyroidism.
They can present as somatic mutations in
thyrotoxic adenomas, as autosomal dominant
familial non-autoimmune hyperthyroidism, or as
sporadic de novo germline mutations [31].
Activating mutations in the downstream G
protein Gsα can also cause non-autoimmune
hyperthyroidism; this occurs through somatic
mosaicism affecting thyroid cells in McCune
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tations in toxic adenomas [82,83]. During preg-
nancy, hCG stimulates iodide transport and
thyroid hormone synthesis through stimulation
of the TSHR. hCG has structural similarity to
TSH and leads to a transient increase in thyroid
hormone synthesis, resulting in lower TSH
levels. In some women, the high hCG levels can
cause overt hyperthyroidism and be associated
with hyperemesis gravidarum. hCG-secreting
trophoblastic tumors (hydatidiform mole,
choriocarcinoma) are rare causes of
hyperthyroidism [84].
1.2) Hypothyroidism
Conditions causing a decreased or absent
response of the TSHR to TSH cause inadequate
iodide uptake and thyroid hormone synthesis.
Autoimmune hypothyroidism can be caused by
the presence of blocking thyrotropin binding
inhibitor immunoglobulins (TBII). These
antibodies cross the placenta and may cause
transient congenital hypothyroidism [85,86].
Resistance to TSH can be caused by molecular
defects affecting the transmission of the TSH
stimulatory signal, most commonly due to
biallelic loss of function mutations of the
TSHR. The phenotypes vary from a hypoplastic
thyroid gland with severe congenital
hypothyroidism to mild hyperthyrotropinemia
with an euthyroid state [87,88]. Inactivating
mutations in the Gsα cause mild
hypothyroidism, such as seen in
pseudohypoparathyroidism [89-91].2) Iodine-induced conditions
Medications or environmental agents can affect
the concentration of intracellular iodide or its
regulatory mechanisms. Amiodarone is an
antiarrhytmic drug that contains two atoms of
iodine in an inner benzene ring, similar to
thyroid hormones. Each 200 mg tablet of
amiodarone contains 75,000 μg of iodine [92]. It
can cause amiodarone-induced thyrotoxicosis
(AIT) via two different mechanisms. AIT type 1,
which occurs more frequently in iodine deficient
areas, is caused by excessive thyroid hormone
synthesis by nodular thyroid tissue that has lost
its autoregulatory capacity (Jod-Basedow
phenomenon; Jod = iodine in German; Karl von
Basedow =German physician who described
thyrotoxicosis associated with exophthalmos and
goiter) [93-97]. The Jod-Basedow effect can be
caused by any form of iodine excess such ascontrast agents or iodine-containing solutions
[98-101]. Currently used, water soluble iodinated
contrast agents provide exposure to about
13,500 μg of free iodine per computerized
tomography (CT) imaging study [92]. AIT type 2
occurs secondary to amiodarone-induced
thyroiditis. Amiodarone can also cause
hypothyroidism (AIH), particularly in patients
with underlying autoimmune thyroid disease.
Lithium is another widely used drug known to
affect thyroid function. Among other effects, it
appears to promote iodide retention in the
thyroid and it decreases the release of thyroid
hormone from the gland [102-104]. Other effects
of amiodarone and lithium are reviewed
elsewhere [93-96,102-105].Consumptive hypothyroidism
Hemangiomas and gastrointestinal stromal tumors may
express high levels of D3. This enzyme catalyzes the
conversion of T4 to rT3 and of T3 to T2, i.e. inactive
forms of thyroid hormone. This causes a unique form of
hypothyroidism due to increased degradation of thyroid
hormones at a rate that exceeds the synthetic capacity of
the stimulated thyroid gland [106-108]. These patients
have significantly elevated rT3 levels and require unusually
large doses of levothyroxine in order to compensate for
the increased degradation of T4 and T3.
Drugs, diet and environmental agents affecting iodide
transport and metabolism
1) Perchlorate, thiocyanate and other
environmental agents
In addition to its iodide transport activity, NIS also
transports other anions [11,109], including
selenocyanate (SeCN−), thiocyanate (SCN−), chlorate
(ClO3−), and nitrate (NO3
−). Pertechnetate (TcO4),
perrhenate (ReO4
−) and perchlorate (ClO4
−) are also
NIS substrates [11]. Perchlorate is a competitive NIS
inhibitor. Perchlorate salts are used as oxidizers in
solid propellants for a wide range of uses;
perchlorate is not biodegradable and it is found in
drinking water, food and multivitamins [110,111].
The Environmental Protection Agency (EPA)
established a minimum reporting level (MRL) of
4 μg/L [112]. Perchlorate can be transported by NIS
into the thyroid and the mammary gland, which
would potentially decrease iodide supply in the
breast milk and affect the newborn’s iodide uptake
by the thyroid gland [113]. Kirk et al. found an
inverse correlation between breast milk iodine and
perchlorate concentration [114]. However, other
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6 months with doses as high as 3 mg/day did not
affect thyroid function [117] and thus, the
consequences of environmental perchlorate
exposure still remain controversial [111].
Thiocyanate is a less potent inhibitor of
NIS-mediated iodide transport than perchlorate.
Exposure to thiocyanate comes mainly from
cigarette smoke (containing cyanide, which is
metabolized to thiocyanate) and from the diet (see
below). Smoking seems to affect iodide secretion
into the breast milk [118]. The available studies
trying to address the effect of smoking on thyroid
function are not conclusive. It appears that smoking
is associated with goiter and hypothyroidism in
iodine deficient regions, whereas smokers have lower
TSH levels in iodine sufficient areas [119,120].
Although the risks of perchlorate and thiocyanate
exposure in healthy adults remain unresolved, a
recent study indicates that a combination of
perchlorate and thiocyanate exposure with low
iodine intake lowers free thyroxine concentration by
about 12% [121]. Nitrates are widely present in soils
and water and come from natural decomposition of
organic materials. Sodium nitrite is also used as a
preservative. The average intake of nitrates in adults
is 75–100 mg/day and 80% comes from vegetables.
Vegetarians may ingest 2.5 times the average intake.
High ingestion of nitrates usually comes from
contaminated water. The EPA defined the maximum
contaminant level at 10 mg/L or 10 ppm [112].
Exposure to high levels of nitrates due to polluted
water has been shown to cause thyroid dysfunction
and goiter [122,123].
2) Medications used to treat hyperthyroidism
The anti-thyroid drugs used in the US include
propyl-thiouracil (6-propyl-2-thiouracil) and
methimazole (1-methyl-2-mercaptoimidazole).
Carbimazole, which is metabolized to methimazole,
is widely used in other parts of the world. These
thionamide drugs are actively concentrated in the
thyroid and their primary effect consists in inhibiting
the TPO-mediated organification [124].ble 4 Radionuclides used for evaluation and management
dionuclide Radioactive emissions (keV*) Half-life
123I γ 159 keV 13.2 hour
131I γ 364 keV 8.09 days
β 637 keV
124I β+ (positron emitter) γ 603 keV 4.2 days
99mTcO4 γ 140 keV 6 hours
eV = kiloelectron volt (1.60217657 × 10−16 joules)3) Diet
Cruciferous vegetables like cabbage, kale, broccoli,
turnips and cauliflower contain glucosinolates.
Cassava (linamarin), lima beans, sweet potatoes,
sorghum and flaxseed contain cyanogenic
glucosides. Both, glucosinolates and cyanogenic
glucosides are metabolized to thiocyanate that
competes for thyroid iodide uptake. These
substances can aggravate iodine deficiency and
contribute to goiter development. Hence, they are
called goitrogens. Soy and millet contains
flavonoids that may inhibit TPO activity. Use of
soy-based formula without added iodide can
produce hypothyroidism and goiter in healthy
infants [125-128].
Iodine as a tool for diagnosis and treatment of thyroid
disorders
The ability of the thyroid to concentrate iodide is widely
used in the diagnosis and treatment of thyroid disorders.
Commonly used diagnostic tests such as the radioactive
iodine uptake and (whole body) scan rely on the ability
of thyroid tissue to concentrate radioactive labeled iodine.
I−131, I−123 and I−124 (a positron emission tomography
(PET) tracer) are the major radionuclide agents used for
the diagnosis of thyroid diseases (Table 4). These tests can
be used to differentiate a hyperactive thyroid, with in-
creased uptake (e.g. Graves’ disease, toxic nodules), from
an underactive thyroid with decreased iodine uptake, sec-
ondary to either thyroid damage or inactivation (e.g. thy-
roiditis, factitious thyrotoxicosis) or a blockade in thyroid
uptake (e.g. mutation in NIS). Whole body scans with
radioactive iodine are useful for the staging and planning
of therapy of well-differentiated thyroid cancer [129]. Be-
cause of the ability of NIS to transport pertechnetate
(TcO4
−), 99mTcO4
−, an isotope with no β emission and a
short half-life, can be used to image thyroid tissue (see
Table 3) [130-132]. The perchlorate (ClO4
−) discharge test
is a functional test that uses ClO4
− to inhibit NIS and
radioactive iodine to diagnose partial or total organifi-
cation defects. This test relies on the fact that iodide
transported into the thyroid is covalently bound to Tg
(organification). Radioactive iodide is administered,of thyroid disorders [132]
Clinical use
s Thyroid and whole body scanning
Thyroid and whole body scanning
Treatment of Graves’ disease, toxic adenomas, thyroid cancer
Whole body scanning Dosimetry
Thyroid scanning
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neck using a gamma camera. Two hours later, uptake
is blocked using the competitive NIS inhibitor ClO4
−
and the radioisotope counts are measured again over
the next hour. Organified iodine is retained, while free,
unbound iodide is washed out. A test is considered
positive if >10% of activity is discharged after ClO4
−
administration. Partial organification defects show a
10-90% discharge, while discharge >90% is consistent
with total organification defect [19,21,133-135].
Iodine in the prevention of thyroid disorders and public
health
Potassium iodide and potassium perchlorate can be used
to protect the thyroid from exposure to I-131 after acci-
dental release from nuclear plant reactors to prevent
hypothyroidism and thyroid cancer [136].
New developments in iodide transport in the diagnosis and
management of thyroid cancer
Poorly differentiated thyroid cancer cells show decreased
or absent iodide uptake. This is associated with decreased
expression or membrane insertion of NIS at the plasma
membrane. For this, reason, there is a great interest in
re-differentiating agents that increase NIS expression
and membrane insertion [11]. For example, selumetinib, a
MAPK (MEK1/MEK2) inhibitor can result in improved
radioactive iodine uptake and retention in some patients
with radioiodide resistant thyroid cancer [137].
Applications of iodide transport outside the thyroid
Outside the thyroid, non-regulated iodide accumulation,
without organification, is known to occur in the lactating
mammary gland, salivary and parotid glands, gastric
mucosa, small intestine, choroid plexus and the ciliary
body of the eye [11,46]. In addition, NIS is expressed in
other tissues [138], however, the physiological relevance
of NIS in these tissues in unclear, except in the lung,
where oxidation of iodide improves anti-viral defenses
[11,139]. Endogenous NIS expression occurs in breast
cancer and cholangiocarcinoma. Currently, ongoing re-
search is exploring the use of 131I− to treat these types
of cancers. The fact that NIS transports perrhenate de-
fines 188ReO4
− as a candidate to increase radiation dose
delivery to these tumors [11]. Transduction of viral vec-
tors containing the cDNA of NIS under the control of
heterologous promoters (e.g. the PSA promoter) are used
experimentally in order to treat other malignancies (such
as prostate cancer) [140].
Conclusions
In conclusion, iodide transport is of essential physio-
logical importance for thyroid hormone synthesis. The
understanding of iodide transport and its regulation hasbeen fundamental in characterizing the spectrum of thy-
roid disorders. The ability of thyroid follicular cells to
concentrate iodide can be used for diagnostic and thera-
peutic purposes and the elucidation of the molecular
events governing iodide uptake also has important im-
plications because it allows to target NIS for re-
differentiation therapies and to use it in non-thyroidal
tissues.
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